There were no clinically pertinent adjustments in comparison with 2011 except for new details and new suggestions with regard to the procedure with bisphosphonates and denosumab (see part ‘Bisphosphonates and RANKL Antibody Denosumab’). part is present or not. The stipulations for just a qualified axillary dissection ended up also https://erichz086ziq4.wikijournalist.com/user